Literature DB >> 11772448

Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney.

Hiroyuki Kusuhara1, Yuichi Sugiyama.   

Abstract

Cumulative studies have revealed the importance of transporters in drug disposition in the body. Recently, organic anion transporters such as organic anion transporting polypeptides (OATPs), organic anion transporters (OATs) and multidrug resistance associated proteins (MRPs) have been identified. Their broad substrate specificity as well as the multiplicity of transporter gene products make these transporters suitable detoxification systems in the body. OATPs and OATs are responsible for the hepatic and renal uptake of organic anions, respectively, while MRP2 is a major transporter involved in the biliary excretion of organic anions. OATPs and MRP2 are involved in the hepatobiliary transport of pravastatin and temocaprilat. These are good examples of hepatobiliary transport maximizing their pharmacological effects, but minimizing their side-effects. Taking into consideration tissue-selective expression and substrate specificity, transporters are useful for delivering small molecules to target tissues. MRPs are also suggested to be involved in the barrier function in the small intestine, blood-brain barrier and blood-cerebrospinal fluid barriers by extruding their ligands into the luminal side. In this manuscript, we have summarized recent studies by others and ourselves on the role of these transporters in the tissue selective distribution and elimination of drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772448     DOI: 10.1016/s0168-3659(01)00480-1

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  30 in total

1.  Transporter database, TP-Search: a web-accessible comprehensive database for research in pharmacokinetics of drugs.

Authors:  Naoki Ozawa; Takako Shimizu; Rika Morita; Yoshiya Yokono; Takafumi Ochiai; Kiyotaka Munesada; Akira Ohashi; Yoshitaka Aida; Yoshimasa Hama; Katsuhiko Taki; Kazuya Maeda; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

2.  LXR alpha transactivates mouse organic solute transporter alpha and beta via IR-1 elements shared with FXR.

Authors:  Masae Okuwaki; Tappei Takada; Yuki Iwayanagi; Saori Koh; Yoshiaki Kariya; Hiroshi Fujii; Hiroshi Suzuki
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

Review 3.  Drug transporters in the central nervous system.

Authors:  Bruno Stieger; Bo Gao
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

Review 4.  Bioavailability of phytochemicals and its enhancement by drug delivery systems.

Authors:  Farrukh Aqil; Radha Munagala; Jeyaprakash Jeyabalan; Manicka V Vadhanam
Journal:  Cancer Lett       Date:  2013-02-19       Impact factor: 8.679

Review 5.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

6.  Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes.

Authors:  Eskouhie H Tchaparian; Jessica S Houghton; Craig Uyeda; Mark P Grillo; Lixia Jin
Journal:  Drug Metab Dispos       Date:  2011-08-24       Impact factor: 3.922

7.  A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier.

Authors:  Corbin J Bachmeier; Donald W Miller
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

8.  Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.

Authors:  Kari T Kivistö; Jörg Zukunft; Ute Hofmann; Mikko Niemi; Sabine Rekersbrink; Swetlana Schneider; Gerd Luippold; Matthias Schwab; Michel Eichelbaum; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

Review 9.  Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions.

Authors:  Li Xing; Yiding Hu; Yurong Lai
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

10.  Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1.

Authors:  A Dreiseitel; B Oosterhuis; K V Vukman; P Schreier; A Oehme; S Locher; G Hajak; P G Sand
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.